@article{uoadl:2997407,
    volume = "348",
    journal = "Journal of Neuroimmunology",
    issn = "0165-5728",
    keywords = "cholinergic receptor antibody;  enzyme antibody;  immunoglobulin;  muscle specific tyrosine kinase antibody;  prednisolone;  pyridostigmine;  rituximab;  unclassified drug;  autoantibody;  autoantigen;  cholinergic receptor;  MUSK protein, human;  protein tyrosine kinase, adult;  antibody detection;  antibody titer;  Article;  bone density;  case report;  clinical article;  clinical feature;  diplopia;  disease severity;  drug dose reduction;  drug efficacy;  dysarthria;  dysphagia;  fatigue;  female;  human;  mastication;  myasthenia gravis;  Myasthenia Gravis Composite scale;  neurologic examination;  priority journal;  radioimmunoprecipitation;  rating scale;  serology;  immunology;  myasthenia gravis, Adult;  Autoantibodies;  Autoantigens;  Female;  Humans;  Myasthenia Gravis;  Receptor Protein-Tyrosine Kinases;  Receptors, Cholinergic",
    BIBTEX_ENTRY = "article",
    year = "2020",
    author = "Zouvelou, V. and Psimenou, E.",
    abstract = "This is a report of an early onset AChR-and MuSK-positive myasthenia gravis. The double seropositivity was detected at the onset of the disease and persisted during 3.5 years follow-up despite the chronic immunotherapy and thymectomy. It is the second reported case of this rare immunological coexistence with sufficient follow-up and available clinical details. At the detection of double positive AChR and MuSK Abs, the treating physician often feels unsecure about the optimal treatment strategy and the long-term prognosis. The detailed clinical record and the long observation of these rare cases, are mandatory for best management in clinical practice. © 2020",
    title = "AChR-and MuSK-positive myasthenia gravis: Double trouble",
    doi = "10.1016/J.JNEUROIM.2020.577364"
}